Semaglutide VS Tirzepatide Semaglutide and tirzepatide are medications that help manage blood sugar and appetite
For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80
Wether or not such injections would in the end also prove cost-effective will remain to be seen
There is a human factor that matters here, too
Setria Glutathione is a patented, clinically researched form shown to raise glutathione status and support immune, liver, and overall recovery health
In addition to its role in diabetes management, liraglutide has been shown to promote weight loss in clinical studies, leading to its approval for obesity treatment under the brand name Saxenda